Peptide News Digest

#Jama

2 stories

Research · View digest

JAMA Viewpoint: The Online Injectable-Peptide Surge Has Outrun Regulation, Researchers Warn

A JAMA Viewpoint published June 15 by researchers from the University of Queensland, the University of Toronto, and the University of California, San Francisco flagged a fast-growing but poorly characterized trend: social-media-promoted injectable peptides for muscle growth, recovery, anti-aging, and cognition. The piece notes 130,000-plus Instagram posts and over 230 million TikTok views as of May 2026, plus a 6x rise in worldwide Google searches for 'peptides' between 2024 (1.3M/month) and 2026 (~8M/month). Substances cited include BPC-157, TB-500, and CJC-1295. The authors call for accelerated safety research and clearer regulation; the piece lands six weeks before the July 23-24 PCAC meeting that will weigh seven of those same substances for 503A compounding status.

Regulatory · View digest

WHO GLP-1 Obesity Treatment Guideline: JAMA Special Communication Continues to Shape Global Coverage Strategy

WHO's December 2025 first-ever GLP-1 guideline for obesity treatment in adults — published as a JAMA Special Communication and updated through Q1 2026 — continues to influence national and payer policy. WHO issued conditional recommendations for chronic GLP-1 therapy as part of comprehensive obesity management, while flagging cost, long-term safety, health-system preparedness, and equity implications. The framework directly informs the political economy of the U.S. Medicare Bridge program extension to 2027 and similar coverage debates globally.